BÜHLMANN fCAL® turbo

Speed, Quality and Flexibility in Calprotectin Quantification

BÜHLMANN fCAL® turbo is a random access calprotectin assay for use on major clinical chemistry platforms.

Utilising immunoturbidimetry it  provides a very rapid and flexible solution for high throughput applications in the routine laboratory. fCAL turbo allows short turnaround time from stool sample to reportable result.

Speed: the fastest calprotectin test in the market.

• Results in 10 minutes.
• Broad measurable range 20 to 8000 µg/g calprotectin reduces the amount of retesting down to <5%.

Quality: The assay is standardised against the BÜHLMANN fCAL^® ELISA, the same cut-offs can be applied. Particle-enhanced turbidimetric immunoassay (PETIA) further increases the precision and reproducibility of calprotectin quantification.

Flexibility: Immunoturbidimetric assays can be applied on any open clinical chemistry platform. This allows random access workflow which can be directly integrated into the existing laboratory infrastructure.

Use with CALEX® Cap device for easy and efficient stool extraction or CALEX® Track for complete automation.

Available Application Protocols:

• Abbott: Architect c-series, Alinity
• Beckman: AU Series (AU400, AU480, AU640, AU680, AU2700, AU5400, AU5800), DxC 600/800
• Mindray: BS-380, BS-200E, BS-400
• Ortho: Vitros 5600
• Roche: Cobas c111, c501, c502, c503, c701, c702
• Siemans: Advia 1650/1800, Advia 2400, Advia XPT, Dimension Vista500/1500*, Atellica
• Thermo Fisher: Konelab30i, Indiko
• The Binding Site: Optilite
• Horiba: ABX Pentra 400
• IDS: iSYS
• BioSystems: BA200

Mark Busbridge, Lead Biomedical Scientist, Charing Cross Hospital reports his experience on moving to the BÜHLMANN fCAL® turbo calprotectin assay:

“We have been analysing faecal samples for calprotectin in-house since 2011. As with most large multi-site NHS Trusts we have seen a significant increase in calprotectin workload during this period, with the Trust currently processing 70-80 samples per day.

Our principle methods have been the Phadia EliA I/II on the ImmunoCAP 100/250 analysers. However, with the increasing sample workload we were struggling to maintain the TAT with our current method, due to prolonged assay time (2 hours), significant ImmunoCAP 250 maintenance downtime and the lengthy sample extraction process.

So in 2018 we began investigating alternative methods. The BÜHLMANN fCAL® turbo calprotectin assay was selected, as this can be run on one of our principle analysers (Abbott Architect C8000). The BÜHLMANN CALEX extraction device process is simple and straightforward for staff to follow, resulting in a much improved workflow compared to the previous method, allowing more staff flexibility in this section.

Since going ‘live’ with the method in late 2019, we have noted improved precision in our inter batch re-extracted patient QC samples, good sample linearity and excellent repeatability and we are currently observing good agreement with our EQA method mean group.”

Videos

Complete Calprotectin Automation with Track CALEX^® from BÜHLMANN

CALEX^® Cap on Clinical Chemistry Analyser

Key Literature